UK Markets closed

SCYNEXIS, Inc. (0L49.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.7650+0.4900 (+21.54%)
At close: 05:30PM BST


1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302-6548
United States
201 884 5485

Full-time employees56

Key executives

NameTitlePayExercisedYear born
Dr. Marco Taglietti M.D.CEO, Pres & Director905.92kN/A1960
Mr. David Gonzalez AnguloChief Medical Officer678.42kN/A1965
Ms. Christine R. Coyne M.B.A.Chief Commercial Officer541.84kN/A1969
Mr. Lawrence R. Hoffman CPA, Esq.Interim Chief Financial OfficerN/AN/A1955
Mr. Scott Sukenick J.D.Gen. Counsel & Corp. Sec.N/AN/A1978
Debbie EtchisonExec. Director of CommunicationsN/AN/AN/A
Dr. Rajeshwar MotheramSr. VP of Pharmaceutical Devel. & Supply ChainN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Corporate governance

SCYNEXIS, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.